Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat Media 3 Stocks Under $5 With Strong Analyst Upside PotentialWritten by Chris Markoch. Originally Published: 2/24/2026. 
In Brief - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
While many investors are rotating out of speculative penny stocks, others still embrace their risk-reward profiles. Stocks trading under $5 carry elevated risk—many are unprofitable or generate little to no revenue. They're typically small-cap companies, which have been beaten up in recent years. Even though the Russell 2000 shows signs of growth, that strength hasn't been widespread across the broader small-cap sector. I Met Elon Musk "Face-to-Face"
During a private gathering of Wall Street elites, I was one of two people selected to speak with Elon personally.
As a result, my research now leads me to believe Elon will announce the SpaceX IPO on this date:
March 26, 2026. Circle it on your calendar.
I'm sharing an "access code" that lets anyone grab a pre-IPO stake before it happens. This is your invitation to the biggest wealth-building event of the decade. Click Here to See how to Get Your "SpaceX Access Code" That could change in 2026 if the economic outlook improves, potentially sending money back into speculative names. As always, quality matters. One way to screen for quality is positive analyst sentiment. These three stocks fit that bill—each lets investors establish a sizable position with a modest outlay and still offers potential for meaningful upside over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging market stocks are expected to be among 2026 winners, but that hasn't been true so far for Grab Holdings Inc. (NASDAQ: GRAB), down about 15% year-to-date. Based in Singapore, Grab operates a super app combining technology, e-commerce and fintech services. A factor in the pullback is its proposed merger with Indonesian ride-hailing firm, GoTo. The deal isn't final and could face significant legislative changes in Indonesia that would constrain earnings potential there. Grab missed the top line slightly in its Q4 2025 earnings report, but context matters: revenue rose 19% year-over-year (YOY), and the company delivered its first full year of profitability. Analysts forecast roughly 120% earnings growth over the next 12 months. That helps explain the bullish sentiment. GRAB stock has a consensus price target of $6.47, roughly 54% above the current price. High-Risk Biotech With Platform Potential Penny stock investors often gravitate to the biotechnology sector, a space defined by high risk and high reward. One contender here is Vaxart Inc. (OTCMKTS: VXRT), the only name on this list that fits the classic penny-stock definition—it traded just over $0.60 at the time of writing. Analyst coverage is light; the sole analyst rating in the past 12 months is a Buy with a $2 target. It's common for analysts to overlook small biotech firms. Vaxart is clinical-stage, meaning all of its candidates are still in clinical trials. The upside is clear: Vaxart is developing oral vaccines for influenza, norovirus and COVID-19. Besides convenience and avoiding needle aversion, the company says its platform can trigger a broader immune response that may induce broader protection. Institutional ownership is only around 18%, but dollar-volume flows favor inflows over outflows by nearly 10:1. Resale Tailwinds Could Turn Today's Losses Into Tomorrow's Gains ThredUp Inc. (NASDAQ: TDUP) is down roughly 33% in 2026, but a longer view shows TDUP up more than 66% over the past 12 months. That suggests the current decline is a normal pullback as investors avoid unprofitable companies. In ThredUp's case, the caveat is "yet." The company runs an online consignment and thrift platform that is gaining traction with Gen Z. Revenue rose 12.5% year-over-year in the most recent quarter. ThredUp cites a GlobalData 2025 survey forecasting U.S. secondhand market gross merchandise value to grow at a 9% compound annual growth rate (CAGR) through 2029. Institutions own roughly 89% of the stock. Net dollar buying has outpaced selling about 2:1, and buyers outnumber sellers about 3:1. However, short interest near 17% adds potential short-term volatility. The consensus price target from six analysts is $12.50, implying more than 190% upside from the current price.
| 
